We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Neurology

Journal Scan / Research · December 16, 2020

Eptinezumab Shows Efficacy in Sustained Prevention of Migraine From Day 1



Additional Info

Disclosure statements are available on the authors' profiles:

Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
Headache 2020 Nov 01;60(10)2220-2231, DW Dodick, C Gottschalk, R Cady, J Hirman, J Smith, S Snapinn

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading